Houria Bachtarzi

Dr Houria Bachtarzi is a Senior Consultant, Regulatory Affairs - Gene and Cell Therapies, with a strong scientific and regulatory experience in the field of advanced biological therapies including virally vectored gene therapy, in vivo and ex vivo gene editing, cell-based immunotherapy, genetically modified cells for tissue regeneration, genetically engineered immune cells targeting cancer cells and stem cell-based therapies. She was previously a Lecturer in Biopharmaceutics and Biotechnology within the Pharmacology and Therapeutics Division and Member of the Brighton Centre for Regenerative Medicine at the School of Pharmacy and Biomolecular Sciences, University of Brighton, UK. Houria completed her PhD in cancer gene therapy/viral gene delivery at the University of Oxford, Department of Oncology, followed by Post-Doctoral research work in AAV-based gene therapy and shRNA therapeutics for degenerative neuro-muscular disorders at the Centre for Biomedical Sciences, Royal Holloway-University of London, in joint collaboration with Benitec Biopharma. Houria holds a First Class Master of Pharmacy Degree (with honours) from the University of Bath, UK and is a Registered Pharmacist with the General Pharmaceutical Council in the UK. She is also a Member of the Royal Pharmaceutical Society of Great Britain (RPSGB) and a Member of the British Society for Gene and Cell Therapy (BSGCT). Houria has published a number of peer reviewed papers in gene therapy and has presented posters and platform presentations at many international and national scientific meetings. In 2014, she received a Rising Star Award from the University of Brighton.

1books edited

1chapters authored

Latest work with IntechOpen by Houria Bachtarzi

Ongoing advances in pharmaceutical biotechnology have paved the way to ground-breaking new biological therapeutic modalities, offering the possibility of a durable curative approach for a number of life-threatening diseases, for which the medical need is as yet unmet. Over the past decades, gene therapy has seen a massive transformation from a proof-of-concept approach to a clinical reality culminating in the regulatory approval of state-of-the-art products in the European Union and in the United States. This book captures some of the scientific progresses notably in gene transfer technologies and translational development of in vivo and ex vivo gene therapy interventions in the treatment of a broad range of complex and debilitating non-inherited and inherited disorders such as: human immunodeficiency virus 1 (HIV-1) infection, cancer, cystic fibrosis, hereditary retinopathies, haemophilia B, cardiac diseases, and chronic liver fibrosis.

Go to the book